Q-omics provides the consensus-scored CCDC92B profile across patient tissues and cancer cell-line models. CCDC92B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC92B is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, CCDC92B RNA expression shows 13,448 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LUSC, and TGCT as cancer lineages where CCDC92B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC92B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC92B survival associations across molecular data types. CCDC92B RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC92B RNA expression–survival associations across cancer types. High CCDC92B expression shows unfavorable associations in UCEC, COAD and ACC, but favorable associations in UVM, LGG and STAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC92B RNA expression.
This table summarizes CCDC92B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC92B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC92B shows lower tumor expression in READ, UCEC and STAD and higher tumor expression in LUSC, BRCA and HNSC. The LUSC box plot shows higher CCDC92B RNA expression in tumor versus normal tissue (log2 FC = +0.171, t-test p = .002).
This table shows molecular features associated with CCDC92B in patient tissues and cancer cell lines. In patient samples, CCDC92B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
